Brief: Maxcyte Sees 2025 Core Revenue To Grow 8% To 15%
12/03/2025 07:20
March 12 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE INC - FY24 NET LOSS $41.1 MILLION VERSUS LOSS OF $37.9 MILLION IN 2023 MAXCYTE INC - SEES 2025 CORE REVENUE TO GROW 8% TO 15% COMPARED TO 2024 Source text: ID:nRSL2752Aa Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview